{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:25:27Z","timestamp":1787307927659,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hengrui Hebei Innovative Development Medical Collaboration Programmeme","award":["HR202501019"],"award-info":[{"award-number":["HR202501019"]}]},{"name":"Hebei Provincial Department of Finance\u2019s Government-Funded Outstanding Talent Program","award":["ZF2025190"],"award-info":[{"award-number":["ZF2025190"]}]},{"award":["ZF2025190"],"award-info":[{"award-number":["ZF2025190"]}],"id":[{"id":"https:\/\/ror.org\/03106nz24","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Pyrotinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated substantial clinical efficacy in patients with HER2-positive breast cancer (BC). However, intrinsic and acquired resistance remain important challenges limiting therapeutic benefit, and reliable biomarkers for predicting pyrotinib response are currently unavailable. This study aimed to identify molecular determinants associated with pyrotinib resistance and uncover their underlying mechanisms. Methods: Pre-treatment tumour samples from an exploratory discovery cohort of 12 patients with HER2-positive BC receiving pyrotinib-containing neoadjuvant therapy were analysed by proteomic profiling. Differentially expressed proteins (DEPs) between the pathological complete response (pCR) and non-pCR groups were integrated with weighted gene co-expression network analysis and protein\u2013protein interaction network analysis to identify candidate proteins. The prognostic relevance of the candidate genes was subsequently evaluated using 127 machine-learning strategies across three independent BC cohorts. Models were ranked according to the mean area under the receiver operating characteristic curve (AUC) across two evaluation cohorts, and SHapley Additive exPlanations (SHAP) analysis was performed separately in both cohorts to prioritise a candidate for subsequent investigation. In vitro and in vivo experiments were then conducted to evaluate the biological role of the prioritised candidate and its association with pyrotinib sensitivity. Finally, the association between pre-treatment SLC27A2 expression and pCR was evaluated in an independent, non-overlapping retrospective cohort of 103 patients receiving pyrotinib-containing neoadjuvant therapy. Results: Exploratory proteomic profiling of 12 pre-treatment tumour samples identified 617 DEPs between the pCR and non-pCR groups. Among 127 machine-learning strategies used to evaluate the prognostic relevance of the candidate genes, the glmBoost\u2013random forest model achieved the highest mean AUC across the two evaluation cohorts (mean AUC = 0.678). SHAP analysis showed that SLC27A2 ranked second in GSE16446 and first in GSE48390 according to mean absolute SHAP values, supporting its prioritisation for subsequent investigation. Functional experiments showed that SLC27A2 promoted proliferation, migration, invasion, and epithelial\u2013mesenchymal transition in HER2-positive BC cells. SLC27A2 knockdown enhanced pyrotinib sensitivity in vitro. In the xenograft experiment using female BALB\/c nude mice, both SLC27A2 knockdown and pyrotinib treatment reduced tumour growth, and a significant interaction between the two factors was observed for endpoint tumour weight (p for interaction = 0.041). Mechanistically, SLC27A2 knockdown reduced lipid accumulation and PPAR\u03b1 expression, whereas pharmacological activation of PPAR\u03b1 partially attenuated the increase in pyrotinib sensitivity induced by SLC27A2 knockdown. Clinical validation further showed that high-pre-treatment SLC27A2 expression was independently associated with a lower likelihood of achieving pCR after pyrotinib-containing neoadjuvant therapy (OR = 0.10, 95% CI: 0.03\u20130.31, p &lt; 0.001). Conclusions: SLC27A2 is a candidate factor associated with BC prognosis and reduced pyrotinib sensitivity in HER2-positive BC. Preclinical findings suggested that PPAR\u03b1-related fatty acid metabolism may contribute to the association between SLC27A2 and pyrotinib response, while clinical validation showed that high-pre-treatment SLC27A2 expression was independently associated with a lower likelihood of achieving pCR following pyrotinib-containing neoadjuvant therapy. These findings support SLC27A2 as a candidate response-associated biomarker and potential therapeutic target, although further mechanistic investigation and external clinical validation are required.<\/jats:p>","DOI":"10.3390\/cancers18162702","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:05:19Z","timestamp":1787241919000},"page":"2702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative Proteomics and Machine Learning Identify SLC27A2 as a Candidate Biomarker and Potential Mediator of Pyrotinib Response in HER2-Positive Breast Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Shiyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"},{"name":"Department of Breast Surgery, Xingtai People\u2019s Hospital, Xingtai 054031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Pain and Rehabilitation, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-1667","authenticated-orcid":false,"given":"Li","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Chang\u2019an District, Shijiazhuang 050010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13058-023-01694-5","article-title":"Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: The time is now","volume":"25","author":"Qi","year":"2023","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41392-023-01689-w","article-title":"Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"ref_5","unstructured":"(2021). Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol., 22, 1139\u20131150."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e076065","DOI":"10.1136\/bmj-2023-076065","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Werter, I.M., Remmelzwaal, S., Burchell, G.L., de Gruijl, T.D., Konings, I.R., van der Vliet, H.J., and Menke-van der Houven van Oordt, C.W. (2022). Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.2139\/ssrn.4147529"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, J., Jiang, Z., Liu, Z., Yang, B., Yang, H., Tang, J., Wang, K., Liu, Y., Wang, H., and Fu, P. (2022). Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): A double-blind, randomized phase 3 trial. BMC Med., 20.","DOI":"10.1186\/s12916-022-02708-3"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.62347\/JQHN3788","article-title":"Efficacy and safety of pyrotinib combined with trastuzumab and chemotherapy in patients with HER2-positive locally advanced breast cancer: A multicenter real-world study","volume":"18","author":"Zhang","year":"2026","journal-title":"Am. J. Transl. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103560","DOI":"10.1016\/j.ebiom.2021.103560","article-title":"Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy","volume":"71","author":"Sha","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ejphar.2015.09.027","article-title":"PPAR\u03b1 regulates tumor progression, foe or friend?","volume":"765","author":"Gao","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1080\/07853890.2022.2139411","article-title":"Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases","volume":"54","author":"Ma","year":"2022","journal-title":"Ann. Med."},{"key":"ref_15","first-page":"101261","article-title":"Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers","volume":"82","author":"Yang","year":"2025","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104680","DOI":"10.1016\/j.drudis.2026.104680","article-title":"The FATP2 axis in cancer: Structural informatics and implications for drug discovery","volume":"31","author":"Wang","year":"2026","journal-title":"Drug Discov. Today"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s12276-025-01440-1","article-title":"SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps","volume":"57","author":"Park","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e24148","DOI":"10.1002\/jcla.24148","article-title":"Upregulated SLC27A2\/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration","volume":"36","author":"Feng","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4149\/neo_2018_180122N48","article-title":"SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer","volume":"65","author":"Chen","year":"2018","journal-title":"Neoplasma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101952","DOI":"10.1016\/j.tranon.2024.101952","article-title":"High expression of SLC27A2 predicts unfavorable prognosis and promotes inhibitory immune infiltration in acute lymphoblastic leukemia","volume":"45","author":"Lu","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1002\/mco2.218","article-title":"Metabolic reprogramming in cancer: Mechanisms and therapeutics","volume":"4","author":"Nong","year":"2023","journal-title":"MedComm"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/s41467-022-32101-w","article-title":"Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells","volume":"13","author":"Tan","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1038\/s41467-024-50998-3","article-title":"Targeting fatty acid oxidation enhances response to HER2-targeted therapy","volume":"15","author":"Nandi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3324\/haematol.2024.287269","article-title":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia","volume":"111","author":"Chen","year":"2026","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10555-024-10170-1","article-title":"Lipid metabolism and its implications in tumor cell plasticity and drug resistance: What we learned thus far?","volume":"43","author":"Vishwa","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/s41467-022-31331-2","article-title":"MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma","volume":"13","author":"Tao","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lin, Y., Wang, Y., and Li, P.F. (2022). PPAR\u03b1: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1074911"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:42:08Z","timestamp":1787305328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":30,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162702"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162702","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}